This article is more than 5 years old. Information may no longer be current.
ISTO Technologies receives CE mark for InQu product line
Click Here to Manage Email Alerts
ISTO Technologies, Inc., an orthobiologics company developing cartilage and bone products for spinal therapy and sports medicine indications, received CE mark approval for its InQu Bone Graft Substitute and Extender.
“The product has proven to be an innovative and cost-effective bone grafting alternative for spinal fusion and other orthopedic surgeries in the United States and we believe that distribution in Europe will augment our domestic revenue growth. We are excited to expand the market for InQu and offer a great alternative for patients in need of bone grafting,” stated Mitchell Seyedin, PhD, president and chief executive officer of ISTO, in a company press release.
According to the release, InQu is a differentiated biomaterial scaffold of synthetic and biologic polymers used mainly in spinal fusion applications. The product is manufactured in four different forms (granules, paste, putty and a 3-D scaffold). The structural component of InQu, polylactide-co-glycolide, creates an osteoconductive scaffold to support new bone formation as it undergoes resorption at the site of implantation. Hyaluronic acid provides improved handling and is reported to exhibit several unique biophysical and biological properties, which play an important role during embryonic development, tissue regeneration and bone repair, according to the release.
InQu was developed by ISTO and launched in the United States in 2008.